Angiopoietin-like proteins in atherosclerosis

Clin Chim Acta. 2021 Oct:521:19-24. doi: 10.1016/j.cca.2021.06.024. Epub 2021 Jun 18.

Abstract

Atherosclerosis, as a chronic inflammatory disease within the arterial wall, is a leading cause of morbidity and mortality worldwide due to its role in myocardial infarction, stroke and peripheral artery disease. Additional evidence is emerging that the angiopoietin-like (ANGPTL) family of proteins participate in the pathology of this disease process via endothelial dysfunction, inflammation, dyslipidemia, calcification, foam cell formation and platelet activation. This review summarizes current knowledge on the ANGPTL family of proteins in atherosclerosis related pathological processes. Moreover, the potential value of ANGPTL family proteins as predictive biomarkers in atherosclerosis is discussed. Given the attractive role of ANGPTL3, ANGPTL4, ANGPTL8 in atherosclerotic dyslipidemia via regulation of lipoprotein lipase (LPL), antisense oligonucleotide or/and monoclonal antibody-based inactivation of these proteins represent potential atherosclerotic therapies.

Keywords: Angiopoietin-like protein; Atherosclerosis; Atherosclerotic calcification; Dyslipidemia; Endothelial cell; Foam cell formation; Inflammation; Platelet activation.

Publication types

  • Review

MeSH terms

  • Angiopoietin-Like Protein 3
  • Angiopoietin-Like Protein 8
  • Angiopoietin-like Proteins
  • Atherosclerosis*
  • Biomarkers
  • Dyslipidemias*
  • Humans
  • Lipoprotein Lipase
  • Peptide Hormones*

Substances

  • ANGPTL3 protein, human
  • ANGPTL8 protein, human
  • Angiopoietin-Like Protein 3
  • Angiopoietin-Like Protein 8
  • Angiopoietin-like Proteins
  • Biomarkers
  • Peptide Hormones
  • Lipoprotein Lipase